Critical Reviews in Therapeutic Drug Carrier Systems最新文献_第10页

Theranostic Nanostructures for Ovarian Cancer. 纳米结构治疗卵巢癌。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CRITREVTHERDRUGCARRIERSYST.2018025589

B. Navyatha, S. Nara

{"title":"Theranostic Nanostructures for Ovarian Cancer.","authors":"B. Navyatha, S. Nara","doi":"10.1615/CRITREVTHERDRUGCARRIERSYST.2018025589","DOIUrl":"https://doi.org/10.1615/CRITREVTHERDRUGCARRIERSYST.2018025589","url":null,"abstract":"Ovarian cancer (OC) has emerged as one of the leading causes of death in women due to the lack of early-stage diagnosis resulting in impairment and delay in treatment of malignancy, which raises the morality rate. Existing diagnostic (pelvic examination, CA125, and enzyme-linked immunosorbent assay) or therapeutic modalities (radiotherapy, abdominal pelvic radiation therapy, and chemotherapy) are insufficient to decrease the 5-year survival rate. Nanoparticles (NPs) have been extensively explored as probes for imaging or therapy of cancer. As an extension of this, probes have been designed to possess both imaging and therapeutic modality in a single molecule and this has emerged as the science of nanotheranostics. This review presents the existing diagnostic and therapeutic strategies in use for OC and discusses their loopholes that limit the prognosis of OC. The review presents a general description of important properties of nanostructures and the type of nanostructures that have been used as imaging/therapeutic probe in cancer. The state-of-the-art nanotheranostics probe for targeting OC is presented. Systematic and complete studies that can correlate the findings of researchers from different global areas are lacking. The current status of nanostructures in various phases of clinical trials and those approved by U.S. Food and Drug Administration (FDA) has been presented. No specific targeted theranostic probe for OC has yet been approved by the FDA. Here, the underlying reasons and the challenges faced for nanotheranostics of OC are discussed, along with its future prospects.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 4 1","pages":"305-371"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CRITREVTHERDRUGCARRIERSYST.2018025589","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies. 胰腺癌：基于纳米制剂疗法的最新进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025459

Preshita Desai, David Ann, Jeffrey Wang, Sunil Prabhu

{"title":"Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies.","authors":"Preshita Desai, David Ann, Jeffrey Wang, Sunil Prabhu","doi":"10.1615/CritRevTherDrugCarrierSyst.2018025459","DOIUrl":"10.1615/CritRevTherDrugCarrierSyst.2018025459","url":null,"abstract":"Pancreatic cancer is the fourth leading cause of death in the United States and has a 5-year life expectancy of ~8%. Currently, only a few drugs have been approved by the United States Food and Drug Administration for pancreatic cancer treatment. Despite available drug therapy and ongoing clinical investigations, the high prevalence and mortality associated with pancreatic cancer mean that there is an unmet chemopreventive and therapeutic need. From ongoing studies with various novel formulations, it is evident that the development of smart drug delivery systems will improve delivery of drug cargo to the pancreatic target site to ensure and enhance the therapeutic/chemoprevention efficacy of existing drugs and newly designed drugs in the future. With this in view, nanotechnology is emerging as a promising avenue to enhance drug delivery to the pancreas via both passive and active targeting mechanisms. Research in this field has grown extensively over the past decade, as is evident from available scientific literature. This review summarizes the recent advances that have brought nanotechnology-based formulations to the forefront of pancreatic cancer treatment.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 1","pages":"59-91"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37000810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solid Lipid Nanoparticles: Vital Characteristics and Prospective Applications in Cancer Treatment. 固体脂质纳米颗粒:在癌症治疗中的重要特性和前景应用。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2019020396

Leontin F Lazăr, Elena Diana Olteanu, Radu Iuga, Claudia Burz, Marcela Achim, Simona Clichici, Lucia R Tefas, Iuliana Nenu, Diana Tudor, Ioana Baldea, Gabriela Adriana Filip

{"title":"Solid Lipid Nanoparticles: Vital Characteristics and Prospective Applications in Cancer Treatment.","authors":"Leontin F Lazăr, Elena Diana Olteanu, Radu Iuga, Claudia Burz, Marcela Achim, Simona Clichici, Lucia R Tefas, Iuliana Nenu, Diana Tudor, Ioana Baldea, Gabriela Adriana Filip","doi":"10.1615/CritRevTherDrugCarrierSyst.2019020396","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2019020396","url":null,"abstract":"Cancer nanotechnology is a new field of interdisciplinary research cutting across biology, chemistry, engineering, and medicine, aiming to lead to major advances in cancer treatment. Over the past several years, solid lipid nanoparticles (SLNs) have attracted the interest of researchers due to their ability to overcome the limitations of classic chemotherapeutics. We reviewed the most recent data on the therapeutic use of SLNs in oncology, presenting their main advantages and disadvantages, along with various production methods and different routes of administration. In accordance with these aspects, the long-term physical stability, the controlled release of the loaded drugs, and the efficient targeted delivery of drugs as methods of surpassing the pharmaceutical limitations of anticancer drugs, natural products and gene therapy have been discussed. In addition, we have also emphasized briefly the crosstalk between SLNs and the new trend in oncology, immunotherapy, as future possible antineoplastic treatment, especially in melanoma. This review highlights the potential of SLNs in providing very positive perspectives for future cancer treatment by improving the efficiency of present chemotherapy and reducing its side effects. SLNs allow targeted delivery of anticancer drugs and could improve the efficiency of current chemotherapy in neoplasia.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 6","pages":"537-581"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37946879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Inhalational Drug Delivery in Pulmonary Aspergillosis. 肺曲霉病的吸入给药。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CRITREVTHERDRUGCARRIERSYST.2018025781

Ranjot Kaur, R. Kaur, C. Singh, Shahdeep Kaur, A. Goyal, K. Singh, Bhupinder Singh

{"title":"Inhalational Drug Delivery in Pulmonary Aspergillosis.","authors":"Ranjot Kaur, R. Kaur, C. Singh, Shahdeep Kaur, A. Goyal, K. Singh, Bhupinder Singh","doi":"10.1615/CRITREVTHERDRUGCARRIERSYST.2018025781","DOIUrl":"https://doi.org/10.1615/CRITREVTHERDRUGCARRIERSYST.2018025781","url":null,"abstract":"Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 3 1","pages":"183-217"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CRITREVTHERDRUGCARRIERSYST.2018025781","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Current Developments in Therapeutic Drug Targeting for the Management of Rheumatoid Arthritis: An Emerging Paradigm. 类风湿性关节炎治疗药物靶向治疗的最新进展:一个新兴的范例。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2019025729

Deeksha R Pai, Madhugiri Prakash Venkatesh, T M Pramod Kumar

{"title":"Current Developments in Therapeutic Drug Targeting for the Management of Rheumatoid Arthritis: An Emerging Paradigm.","authors":"Deeksha R Pai, Madhugiri Prakash Venkatesh, T M Pramod Kumar","doi":"10.1615/CritRevTherDrugCarrierSyst.2019025729","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2019025729","url":null,"abstract":"Rheumatoid arthritis (RA) is a debilitating condition that results in impairment of joints and ligaments and thus constrained mobility and decreased array of movement. It is a broad expression that encompasses additional 100 very diverse disorders mainly affecting joints. In the field of drug discovery, there is no well-known treatment for RA that can eradicate the disease permanently and alleviate the pain. The common non-targeted treatment approaches leads to serious side effects and systemic complications for RA patients. Therefore, targeted drug delivery systems, strategies, and diverse therapeutic approach for treatment of RA have gained increasing attention in the past few years. However, with the current understandings, researchers aim at accomplishing complete and long-lasting remission by the development of smart formulations/smart drug-delivery systems. Treatment for RA patients can be more efficient and effective utilizing these smart approaches. The present review focuses on the existing novel drug-delivery systems, strategies, and current trends in the treatment of RA.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 6","pages":"485-536"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37946878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Dendrimers for Therapeutic Delivery: Compositions, Characterizations, and Current Status. 用于治疗递送的树状大分子:组成、特征和现状。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CRITREVTHERDRUGCARRIERSYST.2018025749

K. Nagpal, Pradeep Kumar, A. Mohan, Sourav Thakur

引用次数: 7

Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs. 纳米载体干粉吸入制剂的评价，特别是抗结核药物。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2018024397

T. Patil, A. Deshpande, P. Shende, Shirish Deshpande, R. Gaud

{"title":"Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.","authors":"T. Patil, A. Deshpande, P. Shende, Shirish Deshpande, R. Gaud","doi":"10.1615/CritRevTherDrugCarrierSyst.2018024397","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024397","url":null,"abstract":"Pulmonary tuberculosis (TB) is a leading cause of death worldwide and is caused by the pathogen Mycobacterium tuberculosis (MTb). As treatment for TB, dry powders for inhalation (DPIs) are considered stable compared with nebulizers and metered dose inhalers and are suitable for high-dose formulations. Although extensive research has been done over the last two to three decades on nanocarrier-based DPIs for targeting MTb infection, none of the anti-TB DPI formulations have reached the market. Challenges in the proper assessment of nanocarrier-based DPIs due to the complexity of lungs is one of the reasons. In this review, the details of in vitro evaluation parameters of nanocarriers and nanocarrier-based DPIs along with their need and basic principles are discussed. Further, the thorough in vitro, ex vivo, and in vivo pharmacological evaluations, together with their procedures wherever required, are covered. The different evaluation parameters during process development, release specifications, and stability studies suggested by U.S. Food and Drug Administration Center for Drug Evaluation and Research to apply for new drug applications and abbreviated new drug applications of DPIs are also discussed. Lastly, the evaluation parameters for DPIs provided in European, United States, British, and Indian pharmacopeias are summarized.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 3 1","pages":"239-276"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CritRevTherDrugCarrierSyst.2018024397","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

In Situ Forming Depot as Sustained-Release Drug Delivery Systems. 原位成形库作为缓释给药系统。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025013

Navjot Kanwar, Vivek Ranjan Sinha

{"title":"In Situ Forming Depot as Sustained-Release Drug Delivery Systems.","authors":"Navjot Kanwar, Vivek Ranjan Sinha","doi":"10.1615/CritRevTherDrugCarrierSyst.2018025013","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018025013","url":null,"abstract":"In situ forming systems can serve as promising alternative to existing long acting injectables like disperse systems and microspheres, owing to their biocompatibility, stability, ease of administration and scale up. Microspheres based on long-acting parenteral systems pose challenges in scaling up and process changes with the drug and polymer selected. In situ gelling systems are having low viscosity which is very conducive during various manufacturing unit operations and passing the formulation through hypodermic needle with lower applied pressure. Different mechanisms such as physical or physiological stimuli and cross linking reactions are involved in the gelling of in situ forming systems at the site of injection. Drug release from in situ forming systems can be altered according to the need by using different polymers, lipids and fatty acids. In situ forming systems can be evaluated by sol-gel transition time, temperature and pH, rheology, gel strength, texture analysis, syringeability and injectability. The present paper is an overview of the various in situ gelling polymers and their application in the preparation of depot formulations. Numerous products based on in situ forming systems such as Eligard®, Atridox® are available in market.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 2","pages":"93-136"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CritRevTherDrugCarrierSyst.2018025013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36999800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Polymeric Mixed Micelles: Improving the Anticancer Efficacy of Single-Copolymer Micelles. 聚合物混合胶束:提高单共聚胶束的抗癌效果。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2019-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2018020481

Arehalli S Manjappa, Popat S Kumbhar, John I Disouza, Vandana B Patravale

{"title":"Polymeric Mixed Micelles: Improving the Anticancer Efficacy of Single-Copolymer Micelles.","authors":"Arehalli S Manjappa, Popat S Kumbhar, John I Disouza, Vandana B Patravale","doi":"10.1615/CritRevTherDrugCarrierSyst.2018020481","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018020481","url":null,"abstract":"Mixed micelles self-assembled from two or more dissimilar block copolymers provide a direct and convenient approach to improved drug delivery. The present review is focused on mixed micelles (prepared from block copolymers only) for various drug delivery applications along with their merits over single-copolymer micelles. Presented are the physicochemical properties of mixed and single-copolymer micelles, various stimuli-responsive mixed micelles for the treatment of cancer, interesting combinations of multifunctional mixed micelles along with their in vitro and in vivo performance, and the potential of mixed micelles as a gene delivery system. Finally, the performance of mixed micelles in preclinical and clinical testing is explained. In addition, the interaction of mixed micelles with cancer cells and the biosafety of mixed micelles are summarized. The in vitro and in vivo performance presented here clearly reveals that the mixed-micelle approach has a wider scope than that of the single-copolymer micelle approach and directs researchers to focus on this approach to delivery of drugs/gene/biologics for various applications.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 1","pages":"1-58"},"PeriodicalIF":2.7,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CritRevTherDrugCarrierSyst.2018020481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37146904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. 胰腺癌治疗的新型药物载体系统和治疗方法的最新进展:一项最新的包容性综述。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2018-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2018019429

Rohit Rajendra Bhosale, Hosahalli Veerabhadrappa Gangadharappa, Devegowda Vishakante Gowda, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Parthasarathi Keshavarao Kulkarni, Koganti Venkata Sairam, Bannimath Gurupadayya

{"title":"Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review.","authors":"Rohit Rajendra Bhosale, Hosahalli Veerabhadrappa Gangadharappa, Devegowda Vishakante Gowda, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Parthasarathi Keshavarao Kulkarni, Koganti Venkata Sairam, Bannimath Gurupadayya","doi":"10.1615/CritRevTherDrugCarrierSyst.2018019429","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018019429","url":null,"abstract":"Pancreatic cancer (PC) is one of the most fatal solid tumors, resulting in more than 250,000 deaths per year globally. It is the eighth leading cause of death from cancer in men and women throughout the world and is now third leading cause of cancer-related deaths in the United States. In addition, the worldwide occurrence of PC ranges from 1 to 10 cases per 100,000 people, indicating a higher incidence in developed countries. Most patients with locally advanced or metastatic disease are not candidates for curative resection due to enormously poor prognosis. Substantial efforts have been taken during the past decade to distinguish better treatments in the absence of efficient screening methods. Regardless of wide-ranging efforts, various systems and therapies have shown insufficient efficacy for PC patients. Therefore, the development of novel drug delivery systems, strategies, and diverse therapeutic approaches to improve the range of active molecules for the treatment of PC is critical. Currently, cancer research focuses on improving the treatment of PC via diverse novel drug delivery systems of chemotherapeutic agents. These novel drug delivery systems consist of nanoparticles and liposomes. Strategies or therapeutic approaches intended for PC include radiation therapy, ablation therapy, and gene therapy. These systems and approaches can carry the drug molecules to targeted cancer cells to enhance the effectiveness of tumor penetration. The present review encloses existing novel drug carrier systems and approaches for PC management.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"35 3","pages":"195-292"},"PeriodicalIF":2.7,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1615/CritRevTherDrugCarrierSyst.2018019429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36267301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10